lundi 9 avril 2018

Onco Actu du 9 avril 2018

1. Biologie

This Scientist Discovered That One Molecule Makes Naked Mole Rats Immune to Cancer. Will it Work in Humans? [Elysium Health]

1.1 Biologie - Gènes

Major milestone reached in effort to ID cancers’ genetic roots [WUSTL]

Study of gene enhancers sheds light on how some cancers form and spread [MD Anderson Cancer Center]

Cancer Genome Atlas studies reveal new insights, set stage for future research and treatment development [Broad Institute]

NIH researchers use genomics to set squamous cell carcinomas apart from other cancers [NIH]

NIH completes in-depth genomic analysis of 33 cancer types [NCI]

2. Etiologie

J&J loses trial over claims linking cancer to asbestos in talc [Reuters]

2.5 Etiologie - Gènes

Hundreds of Inherited Gene Variants Contribute to Cancer [The Scientist]

2.7 Etiologie - Obésité

Is BMI the Best Measure for Obesity? [Cancer Research Catalyst]

3. Prévention

5 ways research can help prevent cancer [Cancer Research UK]

3.2 Prévention - Obésité

Britain's sugar tax on soft drinks comes into effect [Reuters]

Soft drinks sugar tax to tackle obesity ‘has already had an effect’ [Cancer Research UK]

4.1 Dép., diag. & prono. - Prostate

Prostate cancer: Four in 10 cases diagnosed late, charity says [BBC News]

4.12 Biopsies liquides

Putting pathology back in the spotlight [PHG Foundation]

4.2 Dép., diag. & prono. - Génome

Five things to know about direct-to-consumer genetic tests [Johns Hopkins]

Genome sequencing of first 50,000 UK Biobank participants [European Pharmaceutical Review]

5. Traitements

Using mathematical models to determine the best chemotherapy schedules [USC]

Creative Minds: Optimizing Radio-Immunotherapy for Cancer [NIH Director's Blog]

5.1 Traitements - Pré-clinique

Medical studies in humans often launched on faulty evidence base [Reuters]

Halting Intracranial Tumor Growth [Harvard Medical School]

Shoddy Preclinical Data Used in Clinical Trial Proposals [The Scientist]

5.10 Traitements - Essais

Unnecessary exclusions shut patients out of clinical trials [STAT]

5.12.10 Immunothérapies - Fusions et acquisitions

Celgene on biotech hunt with Agios, Jounce in crosshairs: FT [FierceBiotech]

Novartis inks $8.7B AveXis buyout to build gene therapy unit [FierceBiotech]

5.12.3 Immunothérapies-combinaisons

Incyte, Merck Cancer Trial Failure Damages IDO Drugs’ Prospects [Xconomy]

Incyte’s cancer drug fails trial, marking major blow for immunotherapy combination treatment [STAT]

Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma [Business Wire]

Keytruda/epacadostat combo crashes in PhIII melanoma study, raising questions about the future of IDO for Incyte [EndPoints]

5.2.2 Pharma - Fusions & Acquisitions

Roche completes acquisition of Flatiron Health [Roche]

5.3.4 Traitements - AMM (FDA, EMA,...)

Rubraca® (Rucaparib) Approved In The U.S. As Maintenance Treatment Of Recurrent Ovarian Cancer [Clovis Oncology]

5.4 Traitements - Economie

Patients pay the price when hospitals mark up cancer medicines [PhRMA]

Why do new medicines cost so much, and what can we do about it? [The Guardian]

6.12 Ethique

Ethicists find fault with cancer centers marketing their clinical trials as a patient benefit [HealthNewsReview]

6.3 Associations/Fondations

Patient Advocacy Groups Take In Millions From Drugmakers. Is There A Payback? [KHN]

6.7 DMP, Big Data & applis

CancerLinQ CEO Kevin Fitzpatrick to Step Down; ASCO Chief Medical Officer, Richard L. Schilsky, MD, Will Serve as Interim CEO [ASCO]

6.7.1 IA/bioinformatique

Opinion: We Must Make Data More Accessible for Bioinformatics Training [The Scientist]

Bioinformatics for Precision Cancer Medicine [ESMO]

6.7.2 Applis

Apple launches Health Records with 39 health systems. How soon will it reach clinical studies? [FierceBiotech]